Market size, growth to 2033 and clinical trials, side by side.
Kenya is the bigger Alzheimer Drugs market: $3.5 Bn against $14 Mn in 2023, about 251 times as large.
Egypt grows faster: 8.3% a year, against 7.9%. The gap still grows from $3.5 Bn to $7.5 Bn by 2033.
Clinical research: 0 active trials in Kenya, 1 in Egypt.
| Measure | ||
|---|---|---|
| Market size, 2023 | $3.5 Bn | $14 Mn |
| Market size, 2033 projected | $7.5 Bn | $31 Mn |
| Growth a year (CAGR) | 7.9% | 8.3% |
| Money added, 2023–2033 | $4 Bn | $17 Mn |
| Size rank of 24 countries | #1 | #19 |
| Market per person, 2023 | $61 | $0.12 |
| Active clinical trials | 0 | 1 |
| Full report | Kenya report | Egypt report |
Kenya Egypt · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Kenya is the bigger Alzheimer Drugs market: $3.5 Bn against $14 Mn in 2023, about 251 times as large.
Egypt grows faster: 8.3% a year, against 7.9%. The gap still grows from $3.5 Bn to $7.5 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.